- Home
- BBIO
as 11-26-2025 3:37pm EST
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 12.5B | IPO Year: | 2019 |
| Target Price: | $74.79 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $25.34 - $72.26 | Next Earning Date: | 10-29-2025 |
| Revenue: | $353,780,000 | Revenue Growth: | 62.46% |
| Revenue Growth (this year): | 123.32% | Revenue Growth (next year): | 73.46% |
Stock Insider Trading Activity of BridgeBio Pharma Inc. (BBIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kumar Neil | BBIO | Chief Executive Officer | Nov 20 '25 | Sell | $65.86 | 26,156 | $1,722,223.69 | 248,531 | |
| Lo Andrew | BBIO | Director | Nov 18 '25 | Sell | $65.64 | 55,000 | $3,613,069.28 | 50,583 | |
| Scott Randal W. | BBIO | Director | Nov 17 '25 | Sell | $66.57 | 10,000 | $666,465.10 | 17,788 | |
| Lo Andrew | BBIO | Director | Nov 17 '25 | Sell | $66.84 | 40,599 | $2,706,593.15 | 50,583 | |
| Trimarchi Thomas | BBIO | President and CFO | Nov 17 '25 | Sell | $66.52 | 16,934 | $1,125,404.42 | 389,786 | |
| Valantine Hannah | BBIO | Director | Nov 12 '25 | Sell | $66.07 | 25,484 | $1,683,727.88 | 7,465 | |
| Kumar Neil | BBIO | Chief Executive Officer | Nov 7 '25 | Sell | $61.93 | 40,000 | $2,456,994.46 | 248,531 | |
| Kumar Neil | BBIO | Chief Executive Officer | Nov 6 '25 | Sell | $63.62 | 40,000 | $2,526,116.62 | 248,531 | |
| DANIELS RONALD J | BBIO | Director | Nov 6 '25 | Sell | $63.72 | 61,031 | $3,888,999.07 | 16,991 | |
| MCCORMICK FRANK | BBIO | Director | Oct 29 '25 | Sell | $67.39 | 198,359 | $13,206,527.70 | 731,970 |
Latest BridgeBio Pharma Inc. News
BBIO Breaking Stock News: Dive into BBIO Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
BridgeBio to Participate in December Investor Conferences
MT Newswires
3 days ago
BridgeBio Pharma Insider Sold Shares Worth $1,722,224, According to a Recent SEC Filing
MT Newswires
8 days ago
Bridgebio Pharma Insider Sold Shares Worth $6,319,662, According to a Recent SEC Filing
GlobeNewswire
8 days ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
9 days ago
BridgeBio Pharma Insider Sold Shares Worth $1,125,404, According to a Recent SEC Filing
Investor's Business Daily
a month ago
This Pharma Play, The IBD Stock Of The Day, Is Offering Another Entry Amid 100% Advance This Year
Simply Wall St.
2 months ago
BridgeBio Pharma (BBIO) Is Up 5.6% After Acoramidis Shows Broad ATTR-CM Benefit in Phase 3 Data
GlobeNewswire
2 months ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Compare BBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BBIO BridgeBio Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.